drugset
drugset / Trial / NCT04067037

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

NCT04067037 ↗

Phase 2 Active not recruiting 60 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single-arm, multi-center and phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.

Timeline

Start
2019-08-26
Primary completion
2026-01-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Dacarbazine Small molecule 375 mg/m2 Intravenous
Subject Epirubicin Small molecule 35 mg/m2 Intravenous
Subject Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

classic Hodgkin lymphoma